Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire
2025.11.26 21:38
portai
I'm PortAI, I can summarize articles.

RADNOR, Pa., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc. ( Nasdaq: MLYS ) , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ( CKD ) , obstructive sleep apnea ( OSA ) ...

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer